English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech BioTech (Sci&Research)
APOLLOMICS(冠科美博)UPROLESELAN注射液(APL-106)中国I期临床试验第一例受试者成功入组
Mar 04, 2021 11:32 HKT
APOLLOMICS(冠科美博)UPROLESELAN注射液(APL-106)中國I期臨床試驗第一例受試者成功入組
Mar 04, 2021 11:31 HKT
APOLLOMICS, INC ANNOUNCES SUCCESSFUL ENROLLMENT OF FIRST PATIENT INTO PHASE 1 CLINICAL TRIAL OF APL-106 (UPROLESELAN INJECTION) IN CHINA
Mar 04, 2021 11:30 HKT
Alvotech与Cipla Gulf加强合作伙伴关系 在澳洲及新西兰为生物仿制药进行商品化
Mar 04, 2021 10:28 HKT
Alvotech與Cipla Gulf加強合作夥伴關係 在澳洲及新西蘭為生物仿製藥進行商品化
Mar 04, 2021 10:27 HKT
Alvotech and Cipla Gulf Expand Partnership for Commercialization of Biosimilars in Australia and New Zealand
Mar 04, 2021 10:26 HKT
国际罕见病日:贝康医疗宣布为1000个罕见病家庭提供大型公益资助活动,全球首款遗传病阻断试剂盒进入临床试验!
Mar 01, 2021 08:36 HKT
國際罕見病日:貝康醫療宣佈為1000個罕見病家庭提供大型公益資助活動,全球首款遺傳病阻斷試劑盒進入臨床試驗!
Mar 01, 2021 08:35 HKT
中国生物制药旗下北京泰德与Graviton达成海外授权合作协议
Feb 25, 2021 17:33 HKT
中國生物製藥旗下北京泰德與Graviton達成海外授權合作協議
Feb 25, 2021 17:32 HKT
Maculus Therapeutix欢迎Privity,为新型药物输送平台筹集资金
Feb 24, 2021 07:00 HKT
Maculus Therapeutix歡迎Privity,為新型藥物輸送平台籌集資金
Feb 24, 2021 07:00 HKT
Maculus Therapeutix welcomes Privity, Prepares Capital Raise for Novel Drug Delivery Platform
Feb 19, 2021 07:00 HKT
Suntrap Discovered 'LeSoleil' for COVID-19 and the Epidemic
Feb 14, 2021 20:00 HKT
Cofttek, China's Largest Manufacturer of PEA, Draws Attention of Investors
Feb 14, 2021 01:00 HKT
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
Feb 12, 2021 13:00 HKT
APOLLOMICS(冠科美博)在中國和南非引進一款靶向主動免疫檢查點控制劑重組疫苗
Feb 12, 2021 13:00 HKT
APOLLOMICS(冠科美博)在中国和南非引进一款靶向主动免疫检查点控制剂重组疫苗
Feb 12, 2021 13:00 HKT
Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial
Feb 11, 2021 21:00 HKT
Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China
Feb 11, 2021 11:00 HKT
Next >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: